HRT Financial’s Cabaletta Bio CABA Stock Holding History

HRT Financial’s Portfolio CABA Stock Details CABA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$306K	Hold	98,500	–	–	﹤0.01%	3058
2026 Q1	$264K	Buy	+98,500	New	+$274K	﹤0.01%	2979

Other funds holding CABA

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

HRT Financial's CABA Position: Q2 2026 in Review

HRT Financial sold out of Cabaletta Bio (CABA) in Q2 2026, closing a stake of 33,104 shares — an estimated $109K sold.

HRT Financial first reported a position in CABA in Q2 2021 and held it in 7 quarters. The position peaked at $828K in Q1 2023. 139 funds tracked by Wall St. Rank hold CABA as of Q2 2026.

HRT Financial reported no remaining Cabaletta Bio position as of Q2 2026 after selling out during the quarter.
HRT Financial sold 33,104 Cabaletta Bio shares in Q2 2026, an estimated $109K.
HRT Financial first reported a position in Cabaletta Bio in Q2 2021 and held it in 7 quarters.
HRT Financial's Cabaletta Bio position peaked at $828K in Q1 2023.
139 funds tracked by Wall St. Rank held Cabaletta Bio as of Q2 2026.

Based on HRT Financial's 13F filing for Q2 2026, filed 14 Aug 2026.